| Market Capitalization (Millions $) |
213 |
| Shares
Outstanding (Millions) |
43 |
| Employees |
13 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
175 |
| Cash Flow (TTM) (Millions $) |
-3 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Oramed Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development of oral drug delivery systems for the treatment of diabetes and other diseases. The company has developed a proprietary oral insulin capsule as well as an oral GLP-1 analog capsule for the treatment of Type 1 and Type 2 diabetes.
Oramed's technology is based on a platform of orally ingestible capsules containing peptides, proteins, and other molecules that are delivered directly to the small intestine. This approach has been designed to overcome the limitations of traditional insulin injection therapy, which often results in poor patient adherence due to the need for frequent injections and the pain and inconvenience associated with them.
In addition to its diabetes therapies, Oramed is also developing an oral leptin capsule for the treatment of obesity and related metabolic disorders. Leptin is a hormone that plays a key role in regulating energy balance and appetite, and Oramed's oral formulation has the potential to overcome the limitations of injectable leptin therapies.
Oramed was founded in 2006 by Dr. Miriam Kidron, a pharmacist and biochemist, and Nadav Kidron, a lawyer and business executive. The company is headquartered in New York, with research and development facilities located in Jerusalem, Israel.
Since its inception, Oramed has been dedicated to the development of innovative drug delivery technologies that have the potential to transform the treatment of diabetes and other diseases. The company has a strong patent portfolio and an experienced management team with a track record of success in bringing new therapies to market.
Oramed's clinical pipeline includes multiple Phase II and Phase III clinical trials for its diabetes and obesity therapies. The company has received funding and support from prominent investors and organizations, including the Israeli Innovation Authority, the National Institutes of Health, and various venture capital firms.
Overall, Oramed Pharmaceuticals Inc. is a promising biotech company with a strong focus on developing innovative oral drug delivery systems for the treatment of diabetes, obesity, and related metabolic disorders. With a solid pipeline of clinical-stage candidates and a team of experienced researchers and executives, the company has the potential to deliver significant value to patients and investors alike.
Company Address: 1185 Avenue of the Americas New York 10036 NY
Company Phone Number: 967-2633 Stock Exchange / Ticker: NASDAQ ORMP
|
1.82%